Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
In China, S-1 is an novel oral fluoropyrimidine with demonstrated high efficacy on
gastrointestinal cancer. The new regimen with oxaliplatin and leucovorin is expected to
achieve more encouraging efficacy on gastric cancer. This study is aimed to evaluate the
feasibility of the SOL regimen on efficacy and tolerability on Chinese patients with advanced
gastric cancer.